Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion.
J Cell Biol
; 219(9)2020 09 07.
Article
in En
| MEDLINE
| ID: mdl-32858747
Cancer is characterized by genomic instability leading to deletion or amplification of oncogenes or tumor suppressors. However, most of the altered regions are devoid of known cancer drivers. Here, we identify lncRNAs frequently lost or amplified in cancer. Among them, we found amplified lncRNA associated with lung cancer-1 (ALAL-1) as frequently amplified in lung adenocarcinomas. ALAL-1 is also overexpressed in additional tumor types, such as lung squamous carcinoma. The RNA product of ALAL-1 is able to promote the proliferation and tumorigenicity of lung cancer cells. ALAL-1 is a TNFα- and NF-κB-induced cytoplasmic lncRNA that specifically interacts with SART3, regulating the subcellular localization of the protein deubiquitinase USP4 and, in turn, its function in the cell. Interestingly, ALAL-1 expression inversely correlates with the immune infiltration of lung squamous tumors, while tumors with ALAL-1 amplification show lower infiltration of several types of immune cells. We have thus unveiled a pro-oncogenic lncRNA that mediates cancer immune evasion, pointing to a new target for immune potentiation.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
DNA Copy Number Variations
/
Immune Evasion
/
RNA, Long Noncoding
/
Lung Neoplasms
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
J Cell Biol
Year:
2020
Document type:
Article
Affiliation country:
Spain
Country of publication:
United States